NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization76.66 mln
Float6.80 mln
Earnings Date05/12/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
38.00
Transformational upside
Relative Strength
31
/ 100
Underperforming
Debt / Equity
0.09
Debt-free
ROE
-77.89
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Adicet Bio is a Boston-based biotech company focused on developing next-generation cell therapies for patients with autoimmune diseases and cancer. Its leading program uses donor-derived immune cells engineered to seek out and attack a specific protein found on harmful cells driving autoimmune conditions. The company is also advancing a second therapy aimed at a target commonly found in prostate cancer. Founded in 2014, Adicet Bio is currently running clinical trials to test the safety and effectiveness of these treatments.
